Spain In a new study, Spanish researchers identified metastatic cells through a specific marker called the protein CD36, which is related to the uptake of fatty acids in tumor cell membranes. The activity of CD36 and its dependence on lipid metabolism can distinguish metastasis-induced cells from other tumor cells. Researchers have found metastatic CD36 + cells in samples of oral cancer patients with varying degrees of aggressiveness. Among the oral cancers analyzed, a few cells were found to have the ability to initiate metastasis. CD36 is expressed and metastasized in tumors that do not metastasize. In addition, the researchers confirmed that CD36 has the same effect on metastasis of melanoma cells and breast cancer cells. Similarly, statistical analysis of patient samples showed that the metastasis of ovarian cancer, bladder cancer and lung cancer also depends on CD36, and Salvador Aznar Benita, director of the Institute of Stem Cell and Cancer, IRB Barcelona, Spain responded

　　said in the paper: This is a universal mark, and it is also the first transmission-specific mark I know of. "

　　Gloria Pascual, the first author of the paper, said: "To study where the tumor is attached to the tumor, when the tumor separates, why it is sensitive to fat, and other issues.

　　Aznar Benitah pointed out: "We look forward to this research in the scientific community, which will have a significant impact and further promote metastasis research. Research on the potential of CD36 as a metastatic treatment." Hope it can. One question is: Will fat intake directly affect metastasis? The researchers found that the diet of mice is high in fat (fat is 15% higher than the normal diet, the so-called "buffet"). Equivalent to "etiquette meal"). The mice were then inoculated with oral tumor samples, which caused tumor metastasis in 30% of the mice under standard diet conditions. Surprisingly, in the case of high blood lipid content due to eating a high-fat diet, about 80% of the mice caused more and larger metastases. The researchers also tested the effect of certain fatty acid palmitate on migration. This plant-derived fatty acid is the main component of palm oil. Since it is low in coconut oil and other fats, it can be used in many processed foods. They treated oral tumors with palmitic acid for 2 days, and then injected the oral tumors into the mice on a standard diet. They observed that the proportion of these mice with metastatic tumors increased by 50% to 100%. This means that all mice have tumor metastases in a CD36-dependent manner.

　　AznarBenitah said: "In mice inoculated with human tumor cells, there seems to be a direct correlation between fat intake and the increase in CD36-dependent metastasis. Explaining the relationship between diet and metastasis After all, saturated fat has been recorded in developed countries. And a significant increase in sugar intake."

　　ZAznarBenitah has been confirmed in certain tumors, such as colon cancer. Therefore, as this study has confirmed, body functions require fat, but uncontrolled intake can affect health.

　　Is CD36 a therapeutic target for tumor metastasis? This study confirmed the anti-metal chemistry of blocking CD36 protein in immunosuppressed mice and mice with intact immune systems. All test results obtained similar results. When these mice were inoculated with tumor cells, the inhibition of CD36 completely eliminated the possibility of metastasis. In addition, when mice with metastases were injected with antibodies that block CD36, 20% of the mice completely eliminated the metastases, while the number and size of the metastases in other mice accounted for 80%. Significantly reduced by about 90%. Within the treatment window required to achieve the anti-metastatic effect, these mice tolerated the treatment, and no unbearable side effects were observed on autopsy, blood and histology.

　　Researchers are collaborating with the Medical Research Council Technology (MRCTechnology) to jointly develop a new antibody-based anti-CD36 therapy for various cancer patients. If the development of this new therapy is successful, the new product may be launched on the market within 5-10 years.